drugset
drugset / Trial / NCT04110496

Safety and Tolerability of RTX-134 in Adults With Phenylketonuria

NCT04110496 ↗

Phase 1 Terminated 1 enrolled Rubius Therapeutics
NaSingle-groupOpen-labelTreatment

Summary

This study will evaluate the safety and tolerability of RTX-134 in adult patients with PKU.

Timeline

Start
2020-01-29
Primary completion
2022-12-01
Completion
2022-12-01

Outcome

Outcome not reported

Stopped: “The trial was discontinued by the Sponsor”

Drugs

EvaluationDrugModalityDoseRoute
Subject RTX-134 Cell therapy — Intravenous

Indications

phenylketonuria